ResMed (RMD)
(Delayed Data from NYSE)
$205.96 USD
-1.21 (-0.58%)
Updated May 29, 2024 04:00 PM ET
After-Market: $206.00 +0.04 (0.02%) 7:58 PM ET
1-Strong Buy of 5 1
D Value B Growth D Momentum C VGM
Price, Consensus and EPS Surprise
RMD 205.96 -1.21(-0.58%)
Will RMD be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for RMD based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for RMD
Inspira Technologies' (IINN) ART100 Gets FDA 510(k) Grant
Exact Sciences (EXAS) Witnesses Rising Expenses, Competition
RMD: What are Zacks experts saying now?
Zacks Private Portfolio Services
Are Medical Stocks Lagging Mind Medicine MindMed (MNMD) This Year?
Exact Sciences (EXAS) to Showcase Favorable Research Outcome
Here's Why Investors Should Retain ICON (ICLR) Stock Now
Other News for RMD
$100 Invested In ResMed 20 Years Ago Would Be Worth This Much Today
(RMD) - Analyzing ResMed's Short Interest
Developed in Collaboration with Leading Scientists, New ResMed-Supported Research at ATS 2024 Provides Evidence of the Effectiveness and Critical Role of Positive Airway Pressure Therapy
ResMed issues new research, insights into effectiveness of PAP therapy
Betting on Nvidia: 3 ETFs to Own for Exposure to the AI Giant